サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：発作性夜間ヘモグロビン尿症治療薬市場：治療薬別、薬剤別、投与経路別、エンドユーザー別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測
市場調査レポート
商品コード
1351435

発作性夜間ヘモグロビン尿症治療薬市場：治療薬別、薬剤別、投与経路別、エンドユーザー別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測

Paroxysmal Nocturnal Hemoglobinuria Drug Market, By Treatment, By Drugs, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 281 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
発作性夜間ヘモグロビン尿症治療薬市場：治療薬別、薬剤別、投与経路別、エンドユーザー別、国別、地域別：産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2023年09月01日
発行: AnalystView Market Insights
ページ情報: 英文 281 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

発作性夜間ヘモグロビン尿症治療薬の市場規模は2022年に34億7,020万米ドルとなり、2023年から2030年にかけてCAGR 13.8％で拡大

発作性夜間ヘモグロビン尿症治療薬市場- 市場力学：

  • 規制当局の承認と研究開発の拡大が市場成長を牽引
  • 世界の発作性夜間ヘモグロビン尿症治療薬市場の動向は、欧州医薬品庁（EMA）、米国食品医薬品局（FDA）、その他の国際規制機関などの規制当局の承認に大きく依存しています。Eculizumabとravulizumabの市場での存在感と患者へのアクセスのしやすさは、強固な基盤を築いた承認から恩恵を受けています。さらに、新規治療法の発見と既存治療法の強化の試みは、PNH分野における継続的な研究開発の主な目標です。これには、併用薬の研究、革新的な標的治療薬の開発、代替投与技術などが含まれます。このような開発とブレークスルーは、PNH治療薬産業の拡大と発展に貢献しています。

発作性夜間ヘモグロビン尿症治療薬市場-セグメンテーション分析：

  • 発作性夜間ヘモグロビン尿症治療薬の世界市場は、治療法、薬剤、投与経路、エンドユーザー、地域に基づいてセグメント化されます。
  • 治療法に基づき、市場は投薬、サプリメント、輸血、骨髄移植に二分されます。予測期間中、輸血分野が市場を独占すると予想されます。輸血は、貧血の症状を軽減するのに役立つ治療法の一つです。PNHは血栓症を含む大きな副作用を引き起こし、放置すれば死に至ることもあります。PNH患者は貧血症状を治療するために輸血を頻繁に必要とするが、これは輸血中に患者がドナーから血液または血液製剤を受け取るからです。そのため、市場成長の原動力となっています。

発作性夜間ヘモグロビン尿症治療薬市場-地理的洞察

地域的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広がっています。これらの地域は、ビジネスをもたらす国によってさらに分けられます。予測期間中、北米が市場を独占すると予想されます。同地域のPNH治療薬市場を独占しているのは、PNHの標的療法を開発・推進する大手製薬会社です。現在アストラゼネカの一部門となっているアレクシオン・ファーマシューティカルズや、エクリズマブ（ソリリスの名称で販売）のような企業は、市場環境に大きな影響を与えています。さらに、PNH治療薬の承認と入手可能性は、北米、特に米国の規制環境に大きく影響されます。エクリズマブやラブリズマブ（Ultomirisのブランドで販売）など、PNH治療のための標的治療薬が米国食品医薬品局（FDA）により承認され、この領域での広範な使用に寄与しています。

発作性夜間ヘモグロビン尿症治療薬市場-競合情勢：

世界の深海炭化水素探査市場の大手企業は、製品ラインナップを多様化するために研究開発活動を強化しています。さらに、これらの市場参入企業は、成長を促進する戦略的提携やパートナーシップを利用しています。市場で事業を展開する主要企業には、Ra Pharmaceuticals Inc、CinnaGen Co、Akari Therapeutics Plc、Alexion Pharmaceuticals Inc、Apellis Pharmaceuticals、Abbott、NorthStar Rx LLC、Alnylam Pharmaceuticals Inc、F. Hoffmann-La Roche Ltd、Novartis AG、Regeneron Pharmaceuticals Inc、BIOCAD、Samsung Bioepis、Amyndas Pharmaceuticals、Teva Pharmaceutical Industries Ltd、LGM Pharma、Lannett、Achillion Pharmaceuticals Inc、Amgen Incなどがあります。

目次

第1章 発作性夜間ヘモグロビン尿症治療薬市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 発作性夜間ヘモグロビン尿症治療薬の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 発作性夜間ヘモグロビン尿症製薬業界の研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 発作性夜間ヘモグロビン尿症治療薬市場：COVID-19感染症の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 発作性夜間ヘモグロビン尿症の医薬品市場情勢

  • 発作性夜間ヘモグロビン尿症治療薬市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 発作性夜間ヘモグロビン尿症治療薬市場- 治療別

  • 概要
    • 治療別セグメントシェア分析
    • 薬
    • サプリメント
    • 輸血
    • 骨髄移植

第8章 発作性夜間ヘモグロビン尿症治療薬市場- 薬剤別

  • 概要
    • 医薬品別セグメントシェア分析
    • エクリズマブ
    • ラブリズマブ
    • その他

第9章 発作性夜間ヘモグロビン尿症治療薬市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • オーラル
    • 非経口

第10章 発作性夜間ヘモグロビン尿症治療薬市場- エンドユーザー別

  • 概要
    • エンドユーザー別のセグメントシェア分析
    • 病院
    • ホームケア
    • 専門クリニック
    • その他

第11章 発作性夜間ヘモグロビン尿症治療薬市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 発作性夜間ヘモグロビン尿症の製薬産業

  • 競合ダッシュボード
  • 企業プロファイル
    • Ra Pharmaceuticals Inc
    • CinnaGen Co
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Apellis Pharmaceuticals
    • Abbott
    • NorthStar Rx LLC
    • Alnylam Pharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • BIOCAD
    • Samsung Bioepis
    • Amyndas Pharmaceuticals
    • Teva Pharmaceutical Industries Ltd.
    • LGM Pharma.
    • Lannett
    • Achillion Pharmaceuticals Inc
    • Amgen Inc

第13章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Treatment Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Treatment
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Drugs Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drugs
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Route of Administration Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Route of Administration
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User 2018-2030 (USD Million)
  • TABLE Paroxysmal Nocturnal Hemoglobinuria Drug Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Region 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Treatment, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Drugs, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by Route of Administration, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market, by End User, 2018-2030 (USD Million)

List of Figures

  • FIGURE Paroxysmal Nocturnal Hemoglobinuria Drug Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Treatment segment market share analysis, 2022 & 2030
  • FIGURE Treatment segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drugs segment market share analysis, 2022 & 2030
  • FIGURE Drugs segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Route of Administration segment market share analysis, 2022 & 2030
  • FIGURE Route of Administration segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE End User segment market share analysis, 2022 & 2030
  • FIGURE End User segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Paroxysmal Nocturnal Hemoglobinuria Drug Market share and leading players, 2022
  • FIGURE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market share and leading players, 2022
  • FIGURE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market share and leading players, 2022
  • FIGURE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market share and leading players, 2022
  • FIGURE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market share analysis by country, 2022
  • FIGURE Germany Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market share analysis by country, 2022
  • FIGURE India Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Paroxysmal Nocturnal Hemoglobinuria Drug Market share analysis by country, 2022
  • FIGURE Brazil Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Market share analysis by country, 2022
  • FIGURE Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Paroxysmal Nocturnal Hemoglobinuria Drug Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1670

REPORT HIGHLIGHT

Paroxysmal Nocturnal Hemoglobinuria Drug Market size was valued at USD 3,470.2 Million in 2022, expanding at a CAGR of 13.8% from 2023 to 2030.

Red blood cells are destroyed (hemolyzed) and aberrant red blood cells are present in the circulation in paroxysmal nocturnal hemoglobinuria (PNH), an uncommon and possibly fatal blood condition. It results from excessive activation of the complement system, a component of the immune system in charge of removing foreign substances in the body, which is brought on by a genetic mutation that affects the proteins on the surface of red blood cells.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Market Dynamics:

  • Growing regulatory approvals and R&D drives market growth
  • The developments of the worldwide paroxysmal nocturnal hemoglobinuria medicine market heavily depend on regulatory approvals from organizations like the European Medicines Agency (EMA), the U.S. Food and medicine Administration (FDA), and other international regulatory agencies. Eculizumab and ravulizumab's market presence and patient accessibility have benefited from their approval, which has laid a solid basis. Additionally, attempts to discover novel therapy alternatives and enhance existing therapies are the main goals of continuing research and development in the field of PNH. This includes investigating combination medicines, developing innovative targeted therapeutics, and alternate administration techniques. These developments and breakthroughs help the PNH drugs industry expand and develop.

Paroxysmal Nocturnal Hemoglobinuria Drug Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Paroxysmal Nocturnal Hemoglobinuria Drug market is estimated to grow annually at a CAGR of around 13.8% over the forecast period (2023-2030)
  • The Paroxysmal Nocturnal Hemoglobinuria Drug industry is projected to grow at a significant rate owing to the growing regulatory approvals
  • Based on treatment, the blood transfusion segment is expected to dominate the market over the forecast period
  • Based on region, North America is expected to dominate the market over the forecast period

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Segmentation Analysis:

  • The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market is segmented based on treatment, drugs, route of administration, end user, and Region.
  • Based on treatment, the market is bifurcated into medication, supplements, blood transfusion, and bone marrow transplants. The blood transfusion segment is expected to dominate the market over the forecast period. Blood transfusion is one of the therapies that might help to lessen the symptoms of anemia. PNH causes major adverse effects including thrombosis and can be deadly if left untreated. PNH patients frequently require blood transfusions to treat their anemic symptoms because, during a transfusion, the patients receive blood or blood products from a donor. Thus, driving the market growth.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. Major pharmaceutical firms that create and promote targeted therapy for PNH dominate the region's PNH medication market. Companies like Alexion Pharmaceuticals, which is now a division of AstraZeneca, and the medicine eculizumab (marketed under the name Soliris), have had a substantial impact on the market environment. Additionally, the approval and availability of PNH medications are greatly influenced by the regulatory climate in North America, notably the United States. Targeted treatments for the treatment of PNH, such as eculizumab and ravulizumab (marketed under the brand Ultomiris), have been approved by the U.S. Food and Drug Administration (FDA), which has contributed to their extensive usage in the area.

Paroxysmal Nocturnal Hemoglobinuria Drug Market- Competitive Landscape:

Leading companies in the worldwide Deepwater Hydrocarbon Exploration market are stepping up their R&D efforts to diversify their product offerings. Additionally, these market participants use strategic alliances and partnerships that promote growth. The key players operating in the market include Ra Pharmaceuticals Inc, CinnaGen Co, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Apellis Pharmaceuticals, Abbott, NorthStar Rx LLC, Alnylam Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, BIOCAD, Samsung Bioepis, Amyndas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., LGM Pharma., Lannett, Achillion Pharmaceuticals Inc and Amgen Inc.

Recent Developments:

In September 2023, the US Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for crovalimab, an experimental, brand-new anti-C5 recycling monoclonal antibody, to treat paroxysmal nocturnal hemoglobinuria (PNH), according to Chugai Pharmaceutical Co., Ltd. The acceptance was based on the key phase III COMMODORE 2 study's findings, which showed that crovalimab effectively controlled illness and was well tolerated in PNH patients.1 Crovalimab's constant benefit-risk profile as seen in the phase III COMMODORE 1 study's findings provided additional evidence for the application.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET KEY PLAYERS

  • Ra Pharmaceuticals Inc
  • CinnaGen Co
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Apellis Pharmaceuticals
  • Abbott
  • NorthStar Rx LLC
  • Alnylam Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Regeneron Pharmaceuticals Inc
  • BIOCAD
  • Samsung Bioepis
  • Amyndas Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • LGM Pharma.
  • Lannett
  • Achillion Pharmaceuticals Inc
  • Amgen Inc

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY TREATMENT

  • Medication
  • Supplements
  • Blood Transfusion
  • Bone Marrow Transplant

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY DRUGS

  • Eculizumab
  • Ravulizumab
  • Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY ROUTE OF ADMINISTRATION

  • Oral
  • Parenteral

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY END USER

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Treatment
    • 2.1.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Drugs
    • 2.1.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Route of Administration
    • 2.1.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by End User
    • 2.1.5. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Country
    • 2.1.6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Paroxysmal Nocturnal Hemoglobinuria Drug Key Market Trends

  • 3.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Paroxysmal Nocturnal Hemoglobinuria Drug Market Opportunities
  • 3.4. Paroxysmal Nocturnal Hemoglobinuria Drug Market Future Trends

4. Paroxysmal Nocturnal Hemoglobinuria Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Paroxysmal Nocturnal Hemoglobinuria Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Paroxysmal Nocturnal Hemoglobinuria Drug Market Landscape

  • 6.1. Paroxysmal Nocturnal Hemoglobinuria Drug Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Treatment

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
    • 7.1.2. Medication
    • 7.1.3. Supplements
    • 7.1.4. Blood Transfusion
    • 7.1.5. Bone Marrow Transplant

8. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Drugs

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drugs, 2022 & 2030 (%)
    • 8.1.2. Eculizumab
    • 8.1.3. Ravulizumab
    • 8.1.4. Others

9. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
    • 9.1.2. Oral
    • 9.1.3. Parenteral

10. Paroxysmal Nocturnal Hemoglobinuria Drug Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Specialty Clinics
    • 10.1.5. Others

11. Paroxysmal Nocturnal Hemoglobinuria Drug Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Paroxysmal Nocturnal Hemoglobinuria Drug Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Drugs, 2018 - 2030 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

12. Key Vendor Analysis- Paroxysmal Nocturnal Hemoglobinuria Drug Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Ra Pharmaceuticals Inc
    • 12.2.2. CinnaGen Co
    • 12.2.3. Akari Therapeutics Plc
    • 12.2.4. Alexion Pharmaceuticals Inc
    • 12.2.5. Apellis Pharmaceuticals
    • 12.2.6. Abbott
    • 12.2.7. NorthStar Rx LLC
    • 12.2.8. Alnylam Pharmaceuticals Inc
    • 12.2.9. F. Hoffmann-La Roche Ltd
    • 12.2.10. Novartis AG
    • 12.2.11. Regeneron Pharmaceuticals Inc
    • 12.2.12. BIOCAD
    • 12.2.13. Samsung Bioepis
    • 12.2.14. Amyndas Pharmaceuticals
    • 12.2.15. Teva Pharmaceutical Industries Ltd.
    • 12.2.16. LGM Pharma.
    • 12.2.17. Lannett
    • 12.2.18. Achillion Pharmaceuticals Inc
    • 12.2.19. Amgen Inc

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us